By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Jazz Pharmaceuticals 

Corporate Headquarters
Fourth Floor, Connaught House

One Burlington Road
Dublin    4  Ireland
Phone: 353-1-634-7800 Fax: 353-1-634-7850


Jazz Pharmaceuticals plc is an international biopharmaceutical company focused on improving patients’ lives by identifying, developing and commercializing meaningful products that address unmet medical needs. We have a diverse portfolio of products and product candidates, with a focus in the areas of sleep and hematology/oncology. We also support commercial products in therapeutic areas where we can meaningfully address serious medical needs.

As part of our unwavering commitment to improve patients’ lives, we continue to expand our commercial product portfolio and our research and development pipeline in therapeutic areas that can leverage our unique expertise. We do this through a growth strategy of growing sales of the existing products in our portfolio; acquiring additional differentiated products that are on the market or product candidates that are in late-stage development; and pursuing focused development of a pipeline of post-discovery differentiated product candidates.

Our Culture

We have a strong patient-focused culture at Jazz Pharmaceuticals that our employees believe in and pursue every day. It is clearly identified through our mission, vision and core values. Each member of our team makes integral contributions and is working toward a common goal to improve patients' lives. Everything we do at Jazz Pharmaceuticals is focused on three things:
• Putting patients first
• Being a great place to work
• Living our core values — integrity, collaboration, passion, pursuit of excellence and innovation

Key Statistics

Ownership: Public

Web Site: Jazz Pharma
Symbol: JAZZ


Company News
Jazz Pharma (JAZZ) Announces Positive Results From The Phase III TONES 2 Study Of JZP-110 In Narcolepsy Patients With Excessive Sleepiness 4/27/2017 7:02:33 AM
Jazz Pharma (JAZZ) To Report 2017 First Quarter Financial Results On May 9, 2017 4/26/2017 10:14:46 AM
Jazz Pharma (JAZZ) Announces Positive Results From The Phase II/III EXPRESS Study Of Xyrem In Pediatric Patients With Narcolepsy With Cataplexy 4/25/2017 6:45:59 AM
Should You Drop What You're Doing And Buy Jazz Pharma (JAZZ) Stock? 4/10/2017 5:55:33 AM
Jazz Pharma (JAZZ) Reaches Settlement With Hikma (HIK.L) Related To Xyrem Patent Litigation 4/6/2017 6:48:03 AM
Jazz Pharma (JAZZ) Completes Rolling Submission Of New Drug Application For Vyxeos (CPX-351), An Investigational Treatment For Acute Myeloid Leukemia 4/3/2017 7:39:19 AM
Jazz Pharma (JAZZ) And Nippon Shinyaku Co., Ltd. Enter Into License Agreements For The Development And Commercialization Of Defitelio And Vyxeos In Japan 3/30/2017 6:36:15 AM
Jazz Pharma (JAZZ) Announces Positive Results From The Phase III TONES 3 And TONES 4 Studies Of JZP-110 In Patients With Obstructive Sleep Apnea 3/20/2017 7:36:23 AM
Jazz Pharma (JAZZ) Announces First Patient Enrolled In Phase III Clinical Study Evaluating JZP-258 For The Treatment Of Cataplexy And Excessive Daytime Sleepiness In Narcolepsy 3/16/2017 6:35:19 AM
Jazz Pharma (JAZZ) Announces Full Year And Fourth Quarter 2016 Financial Results 3/1/2017 9:50:15 AM